Pregnancy Outcome of Two Patients with Chronic Myelogenous Leukemia Treated with Imatinib

M.A. Mashhadi

Abstract
Although chronic myelogenous leukemia in pregnancy is rare, its management and treatment is more difficult and complicated.

Treatment of patients with chronic myelogenous leukemia includes bone marrow transplantation, however in less than 30% of patients the donor’s organ would be accepted. To this end, cytotoxic therapy is considered as an alternative therapeutic option. This option provides satisfactory hematologic and clinical response, while cytogenetic response is poor.

Imatinib (Gleevec) is a new drug with highly specific efficacy in the treatment of chronic myelogenous leukemia. Prescription of this drug during pregnancy and lactation is not a classic approach and most physicians suggest that this drug should be discontinued during the pregnancy.

Here we report the use of imatinib during the pregnancy in two women with chronic myelogenous leukemia.


Keywords ● Imatinib ● chronic myelogenous leukemia ● pregnancy

Introduction
Chronic myelogenous leukemia (CML) accounts for 20% of newly diagnosed cases of leukemia in adults. The disease has three phases: a chronic phase lasting three to six years that is followed by development of accelerated and/or blastic phases. The cause of CML is translocation of regions of the BCR and ABL genes to form a BCR-ABL fusion gene.

CML can potentially be cured by allogeneic stem-cell transplantation. However, fewer than 30% of patients have matched donors.

Pregnancy accompanied by CML is an uncommon presentation. The management of CML during pregnancy remains a major challenge because of potential side effects on the mother and fetus. Leukapheresis has demonstrated satisfying results in the management of CML. However, this approach has transient effect and does not influence the survival rate and required admission for treatment.

Here, we describe the successful management of two patients with CML in chronic phase using imatinib throughout the pregnancy as the sole modality of treatment.

Case Reports
Case 1
A 20-year-old woman presented in January 2003 with
abdominal pain, early satiety, weakness, night sweating, bone pain, and mild pallor.

On physical examination, spleen was 10-12 cm below costal margin. White blood cell (WBC) count was over 400000/mm³, hemogram and bone marrow aspiration were consistent to CML. The patient was diagnosed as having CML. Cytogenetic study was performed and translocation of 9-22 was documented.

She was managed with hydroxyurea to reduce the WBC count. After decreasing the WBC count to 20000/mm³ imatinib was administered. She was visited monthly by her physician. After 8 months, she was visited by her local physician to control the hemogram while she was receiving imatinib 200 mg/day (initial dose was 400mg/day and adjusted with leukocyte count). In this visit she was diagnosed to be pregnant. She had not stopped imatinib during pregnancy. The drug had been continued and the fetus had been exposed to imatinib in all three trimesters of pregnancy. The major cause for continue the imatinib during pregnancy in this patient was religious belief and when the patient was referred to hematologist, she had a 32-week fetus. She gave birth to a normal healthy baby in March 2005. The baby is now 21 months old and his growth pattern and development are in the normal range. The mother is in normal situation too. Complete blood cell count and ultrasonography of the abdomen in her baby are normal and he does not have any abnormality.

Case 2

A 21-year-old woman was visited in July 2005. She complained of abdominal pain. On physical examination, her spleen was 10 cm below costal margin and her WBC count was 280/000/mm³. She was referred to hematologist for management of splenomegaly and leukocytosis.

Hemogram and bone marrow aspiration showed chronic myeloid leukemia. Cytogenetic study was performed and Philadelphia chromosome was confirmed.

The treatment started by hydroxyurea to reduce the WBC count. Imatinib was administered afterward (400mg/day that was adjusted by leukocyte count). During the treatment with imatinib, she was diagnosed to be pregnant. The hematologist recommended to discontinuing imatinib and terminating the pregnancy but the patient and her husband refused the recommendations. The cause of this decision was religious belief. She continued using imatinib during pregnancy.

She had a normal delivery and her baby was normal after birth. The baby is now 9 months old with normal growth and development. The mother shows complete hematologic remission.

Discussion

Management of CML during pregnancy has not completely been evaluated. The pregnancy dose not compromise the behavior of CML. Bone marrow transplantation is the best and curative approach for CML, however the best pharmacological treatment is imatinib. The therapeutic options for patients with CML and pregnancy are leukapheresis, hydroxyurea, and interferon therapy.

The administration of imatinib for treatment of CML during pregnancy has not been evaluated clinically and the scientific reports on this issue are limited to animal studies. In animal studies, the side effects of imatinib during pregnancy were reported to be decreased weight of testicles and epididymis in male offspring and teratogenicity and postimplantation loss of the fetus.

The best clinical report of pregnancy among patients with chronic myeloid leukemias treated with imatinib has been published by Ault et al. The researchers reported 10 female pregnant patients who consumed imatinib. In their report, the average time of exposure to imatinib was 4 weeks (range 2-9 weeks) and the longest time of exposure was nearly one trimester (<2 months). In our report the exposure time was all the three trimesters of pregnancy. In Ault et al report two spontaneous abortions occurred which were not due to any pathologic condition or family history for pregnancy loss. They reported that the babies had weight loss and one of them had hypospadias with small intestinal malrotation. We did not observe such problems and the two babies had normal growth and development and did not have any abnormalities.

Conclusion

The beneficial effects of treatment with imatinib in pregnant patients with CML should be balanced with the risk of teratogenicity and congenital abnormality in fetus. Similar reports in other countries show that the risk of teratogenicity has been variable and in most cases it is low and is not well established. A more extensive surveillance is needed for better decision making in treating pregnant women with CML.

Conflict of Interest: None declared

References


Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990; 9: 1069-78.